Doximity (DOCS)
Health Care · Digital Health / Professional Networks · NYSE
Doximity is the leading digital professional network for U.S. physicians, connecting them with each other and offering AI-powered productivity tools while providing healthcare enterprises with targeted marketing and recruitment solutions.
What Doximity does
Doximity is a digital platform and professional network specifically for U.S. physicians and other medical professionals, offering tools to streamline clinical workflows, career management, and patient communication. The company monetizes its large user base through marketing, hiring, and workflow solutions sold to pharmaceutical manufacturers and health systems. Its platform leverages data science and AI-powered tools to facilitate medical networking, news delivery, and telehealth services.
Themes: digital health, AI in healthcare / ambient documentation, physician productivity, telehealth, healthcare marketing / advertising, digital recruiting / medical staffing, healthcare SaaS
Fundamentals
- Price$25.33 as of 2026-08-21 close
- Market cap$4.7B as of 2026-08-24
- 1-year return-60.5% 2025-08-21 close $64.13 → 2026-08-21 close $25.33
- P/E28.37 as of 2026-08-24
- Net margin+25.5% as of 2026-08-24
- Gross margin+88.1% as of 2026-08-24
- ROE+17.0% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+11.2% as of 2026-08-24
- Revenue CAGR (3y)+15.5% SEC XBRL
- Beta1.22 as of 2026-08-24
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How DOCS compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 10% 504 covered Health Care peers, as of 2026-08-24
- gross margintop 25% 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
DOCS is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
48.4 #900 of 1,704 scored · #159 of 240 in Health Care
Momentum 76th: over the past 3 months this stock beat the market by 27.5 percentage points; trend 61st: a strong uptrend, with buyers in control; weakest is volume and participation 10th: trading volume is unusually light — only about 42% of its 30-day average.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Doximity looks technically
Doximity (DOCS) is trading 19.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 172 trading days ago — a "death cross", a bearish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 11 trading days ago. It is 66.9% below its highest point of the past year. Trading volume is unusually light — only about 43% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 19.4% below its 200-day average, the long-term trend line — a long-term downtrend | -19.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $22.18 | $22.18 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $31.44 | $31.44 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing high 14 calendar days ago — the swings before that are what the structure reading is measured on | 14 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that upward direction; the labelling fails if price closes below 23.57. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible upward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 172 trading days ago — a "death cross", a bearish long-term signal | 172 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 31, with buyers in control | 31.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 57, neither overbought (above 70) nor oversold (below 30) | 57.2 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($19.88 to $40.00) — its "stochastic" reading is 27 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 27.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $76.51 | $76.51 |
|---|---|---|
| From the 52-week high | it is 66.9% below its 52-week high (its highest price of the past year) | -66.9% |
| Above the 52-week low | it is 47.7% above its 52-week low (its lowest price of the past year) | +47.7% |
| Below the 52-week high | it is 66.9% below its highest point of the past year | 66.9% |
| Since a 20-day breakout | it made a new 20-day high about 11 trading days ago | 11 sessions |
| Since a 55-day breakout | it made a new 55-day high about 11 trading days ago | 11 sessions |
| All-time high | its highest closing price on record is $107.79 (set on 2021-09-10) | $107.79 |
| Given back of the 52-week move | over the past year its closes ranged ($18.01 to $75.12), and it has recovered only a small part of its fall from last year’s high — 13% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $53.30 to $55.13. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 12.8% |
| From the all-time high | it is 76.5% below its all-time high | -76.5% |
| Nearest price level | it is trading 0.8% below a resistance level at $25.53 — a price it turned at twice since 2026-03-23, most recently on 2026-04-17. Since 2024-08-21 it has 3 such levels below the current price and 12 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.8% |
| All-time low | its lowest closing price on record is $17.15 (set on 2026-05-14) | $17.15 |
| Above the all-time low | it is 47.7% above its all-time low | +47.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 72% of it) | 72nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.82 between its high and its low — about 7.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.82 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $19.23 and $28.18 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $19.23 – $23.70 – $28.18 |
| Typical daily range (% of price) | its price moves about 7.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.2% |
| Stretch from the 200-day average | it is trading 3.4 daily ranges below its 200-day average price (19.4% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 43% of its 30-day average | 0.43× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.1% since the prior reading | -0.1% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has softened toward "sell" since the prior reading | 0.10 toward sell |
Candlestick patterns
3
| Since a doji | 3 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 3 sessions ago |
|---|---|---|
| Since a bullish engulfing | 6 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 6 sessions ago |
| Since a bearish engulfing | 5 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 5 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.4% |
|---|---|---|
| Open gap | it gapped 4.0% below the previous close 9 sessions ago and has not traded back through the level it left behind at 27.4 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -4.0% |
| Gap filled | a 2.1% gap up opened on 2026-07-24 has been "filled" 20 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 20 sessions ago |
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 17.7 percentage points (the stock gained 20.0% while the market gained 2.3%) | +17.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 27.5 percentage points (the stock gained 30.6% while the market gained 3.1%) | +27.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 11.9 percentage points (the stock lost 0.9% while the market gained 11.1%) | -11.9% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 81.0 percentage points (the stock lost 60.5% while the market gained 20.5%) | -81.0% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, MACD momentum is positive, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 16% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thin, spanning 0.1% of the share price, which is taken to mean a barrier that gives way easily. | +15.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is sitting right on the average price paid so far this year, so the typical buyer over that stretch is roughly break-even. That average is $25.31 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +0.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 1% below the average price paid since it last reported on 2026-08-06 (its 10-Q), so the typical buyer over that stretch is under water. That average is $25.57 — a volume-weighted average of daily closes over 12 sessions, not a true tick-by-tick VWAP. | -0.9% |
Price levels it has turned at before
DOCS last closed at $25.33 on 2026-08-21. Since 2024-08-21 it has turned at 3 prices below its last close and 12 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $25.53 | Resistance | 0.8% above the last close | turned there twice · 2026-03-23 to 2026-04-17 |
| $26.89 | Resistance | 6.2% above the last close | turned there twice · 2026-03-05 to 2026-05-12 |
| $23.59 | Support | 6.9% below the last close | turned there three times · 2026-02-06 to 2026-07-07 |
| $22.72 | Support | 10.3% below the last close | turned there three times · 2026-04-23 to 2026-07-15 |
| $19.90 | Support | 21.4% below the last close | turned there three times · 2026-06-25 to 2026-08-06 |
| $43.23 | Resistance | 70.7% above the last close | turned there twice · 2025-12-23 to 2026-01-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes below $23.57.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $29.94 and $35.25 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close above $40.00.
This reading has stood for 6 trading days, since 2026-08-14.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · in a strong, established uptrend (ADX) · lagging the market · Most volatile (6%+ typical daily range) · Trading at this year’s average price paid (anchored VWAP) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.52 mean, 1=Strong Buy…5=Strong Sell) — 18 analysts
- Mean price target$29.39 range $18.00 – $47.00; median $28.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for DOCS
- Consensus EPS estimate$0.3513 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on a relatively small number of large pharmaceutical and health system customers for a significant portion of revenue.","Ability to maintain and grow platform engagement amidst rapid technological changes in AI and digital health.","Exposure to risks related to data privacy, cybersecurity, and evolving healthcare regulatory requirements."]
What changed in the latest 10-Q
AI-assisted comparison of DOCS's 10-Q filed 2026-02-05 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-02-05) states member coverage as 'more than 85% of U.S. physicians' vs. older filing (2025-11-06) which stated 'more than 80%'
- Newer filing reports three months ended December 31, 2025 revenue of $185.1 million and nine months ended December 31, 2025 revenue of $499.5 million
- Newer filing reports three months ended December 31, 2025 net income of $61.6 million and adjusted EBITDA of $111.4 million; nine months ended December 31, 2025 net income of $176.9 million and adjusted EBITDA of $292.0 million
- Removed:
- Older filing (2025-11-06) reported three months ended September 30, 2025 revenue of $168.5 million with 23% year-over-year growth rate
- Older filing reported six months ended September 30, 2025 revenue of $314.4 million with 19% year-over-year growth rate
- Older filing reported three months ended September 30, 2025 net income of $62.1 million and adjusted EBITDA of $100.8 million
- Older filing reported six months ended September 30, 2025 net income of $115.4 million and adjusted EBITDA of $180.6 million
- Older filing included customer metrics as of September 30, 2025 (121 customers with at least $500,000 revenue; 118% net revenue retention rate)
- Reworded:
- Metric period changed from 'September 30, 2025' in older filing to 'December 31, 2025' in newer filing for customers with at least $500,000 revenue and net revenue retention rate
- Three-month and six-month comparison periods replaced with three-month and nine-month comparison periods in newer filing
- Notes:
- The texts reflect different reporting periods (Q2 2025 vs. Q3 2025 for the older filing; Q3 2025 for the newer filing), so changes represent updated quarterly results rather than revisions to prior disclosures
- Customers with $500,000+ revenue metric increased from 121 to 126 between periods, but this reflects business progression rather than restatement
- Net revenue retention rate decreased from 118% to 112% between the two reporting periods shown
Risk Factors
- Reworded:
- Balance sheet comparison date changed from September 30, 2025 to December 31, 2025 in the newer filing (filed 2026-02-05)
- Cash and cash equivalents decreased from $169,249 thousand (September 30, 2025) to $64,838 thousand (December 31, 2025)
- Marketable securities decreased from $709,118 thousand (September 30, 2025) to $670,288 thousand (December 31, 2025)
- Accounts receivable increased from $129,306 thousand (September 30, 2025) to $156,589 thousand (December 31, 2025)
- Prepaid expenses and other current assets increased from $84,527 thousand (September 30, 2025) to $101,738 thousand (December 31, 2025)
- Total current assets decreased from $1,092,200 thousand (September 30, 2025) to $993,453 thousand (December 31, 2025)
- Property and equipment, net increased from $15,712 thousand (September 30, 2025) to $17,055 thousand (December 31, 2025)
- Deferred income tax assets decreased from $15,074 thousand (September 30, 2025) to $14,842 thousand (December 31, 2025)
- Operating lease right-of-use assets decreased from $7,982 thousand (September 30, 2025) to $7,523 thousand (December 31, 2025)
- Intangible assets, net decreased from $39,143 thousand (September 30, 2025) to $37,266 thousand (December 31, 2025)
- Total assets decreased from $1,257,109 thousand (September 30, 2025) to $1,157,026 thousand (December 31, 2025)
- Accounts payable increased from $4,391 thousand (September 30, 2025) to $4,785 thousand (December 31, 2025)
- Accrued expenses and other current liabilities increased from $33,722 thousand (September 30, 2025) to $76,677 thousand (December 31, 2025)
- Deferred revenue, current decreased from $100,034 thousand (September 30, 2025) to $66,307 thousand (December 31, 2025)
- Operating lease liabilities, current decreased from $2,123 thousand (September 30, 2025) to $2,079 thousand (December 31, 2025)
- Total current liabilities increased from $140,270 thousand (September 30, 2025) to $149,848 thousand (December 31, 2025)
- Deferred revenue, non-current decreased from $263 thousand (September 30, 2025) to $174 thousand (December 31, 2025)
- Operating lease liabilities, non-current decreased from $9,146 thousand (September 30, 2025) to $8,613 thousand (December 31, 2025)
- Other liabilities, non-current increased from $11,899 thousand (September 30, 2025) to $19,093 thousand (December 31, 2025)
- Total liabilities increased from $161,578 thousand (September 30, 2025) to $177,728 thousand (December 31, 2025)
- Notes:
- The forward-looking statements section is identical in both filings and contains no changes
- Only the balance sheet date and corresponding financial figures differ between the two filings; the underlying disclosure structure and forward-looking statements language remain unchanged
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($88021) — 1 selling insider
- Last 180 days0 buys · 6 sells ($492082) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-15. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about DOCS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 2 matched disclosures for DOCS from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding DOCS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 23,305,260
- Reported value $543,012,578
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 3 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
DOCS had 24,572,759 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for DOCS because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 24,572,759
- Prior settlement (shares) 20,733,516
- Reported change 18.52%
- Days to cover (reported) 7.99
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- LinkedIn (MSFT)
- WebMD (KKR)
- Medscape (KKR)
- Sermo
- Epic Systems
- Teladoc Health (TDOC)
- Amwell (AMWL)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare DOCS vs…
Frequently asked questions
What does Doximity (DOCS) do?
Doximity is a digital platform and professional network specifically for U.S. physicians and other medical professionals, offering tools to streamline clinical workflows, career management, and patient communication. The company monetizes its large user base through marketing, hiring, and workflow solutions sold to pharmaceutical manufacturers and health systems. Its platform leverages data science and AI-powered tools to facilitate medical networking, news delivery, and telehealth services.
What sector is Doximity (DOCS) in?
Doximity (DOCS) is classified in the Health Care sector. Its industry is Digital Health / Professional Networks. It trades on NYSE.
Who are Doximity's (DOCS) competitors?
Notable peers of Doximity (DOCS) include LinkedIn, WebMD, Medscape, Sermo and Epic Systems. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in DOCS?
Yes — we hold 2 matched STOCK Act disclosures for DOCS from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Doximity (DOCS) overbought or oversold right now?
Doximity (DOCS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 57, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on DOCS come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.